美国临床试验数据库Clinicaltrials数据显示,截至2023年11月10日,中国CAR-T细胞疗法临床研究数量达到655个,居世界第一,这也是中国首次在一个新药研发领域走到国际前列。其中,传奇生物的西达基奥仑赛、科济药业的Claudin18.2 CAR-T都达到全球...
实体瘤含有混合的细胞群,使得一些癌细胞即使在接受CAR-T细胞治疗后仍能继续躲避免疫系统的检测。 Maus团队正在努力克服肿瘤异质性带来的挑战,他们采用了一种创新策略,将以前两种独立的策略结合在一起:CAR-T细胞 和双特异性抗体,即 T 细胞结合抗体分子(T-cell engaging antibody molecules, TEAMs)。用于治疗GBM的CARv3...
参考资料: [1] City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial. Retrieved March 7, 2024, from https://www.businesswire.com/news/home/20240307463963/en [2] Brown et al., (2024). Loco...
Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company developing treatments for patients with cancer, autoimmune and viral diseases. Originating from clinical experience at Memorial Sloan Kettering and QIMR Berghofer, Atara’s off-the-shelf, allogeneic, T c...
Wei Sun, Ai-Bin Liang, He Huang, Xiao-Jun Huang. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience. Haematologica. 2023 Aug 1;108(8):2011-2028. doi: 10.3324/haematol.2022.282316....
2.Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China | Blood | American Society of Hematology (ashpublications.org)...
[9]Granit V, Benatar M, Kurtoglu M, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Lancet Neurol. 2023 Jul;22(7):578-590. doi: 10.1...
[4] Xu Y, Xiang Z, Alnaggar M, et al. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021;18(2):427-439. ...
Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021;18(2):427-439. [5] Lo Presti E, Pizzolato G, Corsale AM, et al. γδ T Cells and Tumor Microenvironment: ...
CAR-T挑战脑瘤,一项关键I期临床结果公布 CAR-T细胞疗法为血癌治疗带来了革命性突破,但实体瘤适应症仍在攻克中。3月7日,最新发表在Nature Medicine杂志上的一项研究显示,由美国City of Hope开展的一项用于治疗胶质母细胞瘤的开创性I期试验(NCT02208362)显示,CAR-T细胞疗法对这类极具侵袭性的脑肿瘤显示出良好的临床...